logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Eight drug projects of small Spanish companies attract the interest of pharmaceutical companies

New meeting of the Farma-Biotech program, which brings start-ups and research groups into contact with national and international pharmaceutical companies to promote preclinical research and facilitate development

Source: www.consalud.es

Up to eight new research projects led by small companies and by Spanish public research centers may be promoted thanks to the collaboration with pharmaceutical companies. This is what a new meeting has achieved within the Farma-Biotech program, promoted by Farmaindustria and whose objective is precisely to facilitate collaboration between research groups and the pharmaceutical industry so that promising projects in the preclinical phase do not lose the opportunity for development due to lack of support from a company with knowledge, experience and financial muscle capable of driving the long, expensive and risky R&D process of a drug.

This joint meeting project was launched by Farmaindustria in 2011 with a double objective: to promote biomedical research in Spain through the collaboration of start-ups and research teams from public or private centers with the large international decision-making centers of Biomedical R&D and accelerating the translation of new drugs from these small companies to medical practice.

Since its launch in 2011, this collaborative initiative is driving the development of more than 45 new molecules

“Increasingly, biomedical research is open and collaborative. In essence, the Farma-Biotech program tries to contribute to the fact that research projects that are being carried out in Spain in the field of human health may have the option of overcoming the preclinical phase and have more possibilities for development. It is the pharmaceutical companies that have the capacity to give the impetus without which most projects would have enormous difficulties in reaching the most advanced phases of clinical research. This type of collaboration is common in our sector and pays off, as we are seeing in the current research on treatments and vaccines against Covid-19 ”, says Javier Urzay, Deputy Director General of Farmaindustria.

Since the start of this program, more than 500 promising research projects have been evaluated, of which more than a hundred fit the selection criteria proposed by the program (innovative proposal of the world SCOPE, differentiated from the rest, with sufficient progress technical and industrial protection). This collaborative initiative is currently driving the progress of more than 45 new molecules that are under development and protected by patents.

PROJECTS IN ONCOLOGY, ALZHEIMER AND RARE DISEASES

The proposals presented at the last meeting, still in the preclinical phase –before the human trials-, were presented and debated between the researchers themselves and a score of large pharmaceutical companies via telematics. On this occasion, the eight selected preclinical research projects that have attracted the interest of the pharmaceutical industry are on drugs for diseases related to oncology, infectious diseases, Alzheimer’s, allergies, the cardiovascular system and rare diseases.

One of the most important characteristics of this initiative of Farmaindustria is the promotion of public-private collaboration, since, of the eight projects, six are promoted by health research institutes and public centers of excellence, such as the National Center for Cardiovascular Research (CNIC), the National Cancer Research Center (CNIO), the August Pi i Sunyer Biomedical Research Institute (Idibaps-Ciberer) or the Autonomous University of Barcelona. These projects have been presented together with research from the biotechnology companies InnoUp Pharma and SOM Biotech.

On the part of the industry, a total of 18 laboratories, both national and multinational, attended the Farmaindustria call, which previously selected the projects based on their potential so that they could represent a real opportunity for cooperation for both parties. Thus, the eight investigations have reached an adequate degree of maturity to study possible agreements with the companies.

A MODEL OF SUCCESS

After nine years of existence, the data from the Farma-Biotech program reflect the existing scientific potential in Spain in the field of biomedical research and the capacity of the innovative pharmaceutical industry to attract and advance this talent, but also the enormous difficulties that exist to turn an idea into reality in the world of new drug development. It must be emphasized that researching and developing a drug, from the preclinical phase until it reaches the patient, requires a period of between 10-12 years and an investment of close to 2,500 million euros. The high risk must be emphasized, given that only 10% of the potential drugs that manage to reach the clinical phase (in which they are already tested in patients) will one day be available to patients.

The Farma-Biotech program is part of the Spanish Technological Platform for Innovative Medicines, which has the support of the Ministry of Science and Innovation and which, together with the BEST program, aimed at clinical research, contributes to promoting the commitment of pharmaceutical companies for research in Spain. Thus, investment in the R&D sector broke a new record in 2019, reaching 1,211 million euros, almost 20% of all industrial R&D carried out in our country, according to the latest Survey on R&D Activities. D that Farmaindustria carries out among its associates.

This report also highlights how in the last decade the weight of research projects developed in collaboration with hospitals and public and private centers (extramural spending) has grown 3.6 percentage points, a chapter that represents 43.6% of the total investment of pharmaceutical companies and that translates to 528 million euros in 2019, while intramural investment (that made in the research centers of the companies themselves) exceeded 683 million euros.

Collaboration among all is essential to be able to advance in the research sector. Only by collaborating with each other will we be able to carry out promising projects

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.